(2) limited by relatively small numbers of patients, few study reported the effect of first‐line chemotherapy in NSCLC patients with BRAF mutations; (3) they also did not compare the effect of first‐line chemotherapy in BRAF‐mutant patients with patients who harbored other activating mutations such as EGFR and KRAS. We therefore conducted this study with the aim of clarifying the clinicopathologic characteristics and effect of chemotherapy in Chinese patients with BRAF‐mutant NSCLC. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.